A Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of actinium-225-macropa-pelgifatamab (BAY 3546828) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)
Principal Investigator: Veera Ahtiainen
Trial site: HUS Comprehensive Cancer Center
